AAO Updates HCQ Retinopathy Guidance
Updated recommendations emphasize dosing limits and screening for toxicity risk.
By
Andrea Surnit
April 23, 2026
Clinical Scorecard: AAO Updates HCQ Retinopathy Guidance
At a Glance
Category Detail
Condition Hydroxychloroquine Retinopathy Key Mechanisms Risk of retinopathy associated with hydroxychloroquine use, influenced by dosing and screening practices. Target Population Long-term users of hydroxychloroquine, predominantly female, with conditions such as systemic lupus erythematosus and rheumatoid arthritis. Care Setting Ophthalmology clinics and primary care settings.
Key Highlights
Risk of toxicity is less than 1% within 5 years at recommended dosing. Annual screening is advised, with baseline screening recommended near treatment initiation. Risk of toxicity increases with higher doses and longer duration of use. New technologies like AI-based imaging analysis show potential but are not yet validated for routine use. Retinopathy detection at mild stages is crucial to prevent progression. Guideline-Based Recommendations
Diagnosis
Baseline screening with optical coherence tomography (OCT) and fundus autofluorescence (FAF) is recommended. Management
Maintain dosing at no more than 5 mg/kg/day of real body weight. Monitoring & Follow-up
Annual screening during therapy; may be deferred for up to 5 years in patients without major risk factors. Risks
Increased risk of toxicity in patients with renal disease, older age at treatment initiation, or concurrent use of tamoxifen. Patient & Prescribing Data
Patients receiving hydroxychloroquine for chronic conditions.
With proper dosing and screening, most patients can safely use HCQ for decades.
Clinical Best Practices
Utilize OCT and FAF as primary screening tools. Implement annual monitoring for long-term HCQ users. Educate patients on the importance of adherence to dosing and screening recommendations. Related Resources & Content
